Investor Deadline for ImmunityBio Class Action Lawsuit on May 26

A class action lawsuit has been filed against biotechnology company ImmunityBio (NASDAQ: IBRX) alleging misleading statements regarding its lead product Anktiva. Investors who purchased securities between January 19, 2026 and March 24, 2026 have until May 26 to seek appointment as lead plaintiff.

By Robbins Geller Rudman & Dowd LLP · PR Newswire · May 21, 2026, 21:18 UTC

Tickers: $IBRX

Topics: biotechnology FDA warning letter securities fraud

Read the full article at PR Newswire

More Politics news

Pomerantz Law Firm Investigates HCA Healthcare Following Reduced Profit Guidance PR Newswire · November 12, 2026, 16:25 UTC
Pomerantz Law Firm Investigates Greenland Energy (GLND) Following Short Seller Report PR Newswire · November 12, 2026, 16:15 UTC
Pomerantz Law Firm Investigates Potential Securities Fraud at Foghorn Therapeutics (FHTX) PR Newswire · November 12, 2026, 16:00 UTC
Pomerantz Law Firm Investigates VinFast Auto Ltd. Following Significant Operating Losses PR Newswire · November 12, 2026, 15:55 UTC
Class Action Lawsuit Filed Against Skechers U.S.A., Inc. Regarding Take-Private Acquisition PR Newswire · November 12, 2026, 15:00 UTC
Class Action Lawsuit Filed Against Compass, Inc. Regarding Merger Disclosures PR Newswire · November 12, 2026, 15:00 UTC
Scott Colom Defeats Incumbent Cindy Hyde-Smith in Mississippi Senate Election CNBC · November 11, 2026, 23:03 UTC
Advocacy Groups Prepare to Pressure Politicians Over Data Center Restrictions Following Midterm Elections The Verge · November 11, 2026, 21:56 UTC
Alleged Security Concerns Involving Nvidia CEO Jensen Huang Prompt US-Taiwan Official Concern The Verge · November 11, 2026, 19:22 UTC
Scott Colom Maintains Narrow Lead Over Cindy Hyde-Smith in Mississippi Senate Race CNBC · November 10, 2026, 21:55 UTC